Develops RNA-based therapeutics delivered directly to the respiratory tract without using lipid nanoparticles, targeting viral respiratory infections and certain cancers. The proprietary NEED™ delivery platform enables precise treatment, addressing high unmet medical needs in conditions like asthma and cystic fibrosis.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current RNA-based therapeutics often rely on lipid nanoparticles (LNPs) for delivery, which can present challenges in targeted delivery and potential toxicity, especially in respiratory applications. Effective delivery of RNA therapeutics to the respiratory tract remains a significant hurdle for treating various pulmonary diseases.
Solution
RIGImmune is developing RNA therapeutics for respiratory diseases, utilizing a proprietary non-LNP delivery platform called NEED™ for targeted delivery directly to the respiratory tract. The NEED™ platform overcomes the limitations of LNP-based delivery by enabling efficient and precise delivery of RNA compounds to the lungs. This targeted approach aims to enhance the innate immune response against viral respiratory infections and address unmet medical needs in conditions such as asthma and cystic fibrosis. RIGImmune's lead products, RIG-101 and RIG-301, are designed to stimulate the RIG-I pathway and deliver CFTR mRNA, respectively, offering potential treatments for these respiratory ailments.
Target Audience
RIGImmune's primary target audience includes patients suffering from respiratory diseases with high unmet medical needs, such as asthma, cystic fibrosis, and viral respiratory infections, as well as pharmaceutical companies seeking innovative delivery platforms for RNA therapeutics.
Features
- NEED™ Delivery Platform: A proprietary nano-emulsion technology for non-LNP delivery of RNA therapeutics.
- Targeted Respiratory Delivery: Enables precise delivery of RNA directly to the respiratory tract, enhancing therapeutic efficacy.
- RIG-101: An antiviral interferon booster designed to enhance the innate immune response against viral respiratory diseases.
- RIG-301: A CFTR mRNA therapeutic aimed at treating cystic fibrosis by delivering functional CFTR mRNA to the lungs.
- Stem-loop RNA therapeutics (SLRs): A novel class of oligonucleotides with unique therapeutic properties.